Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ABBV-514 study alone and with budigalimab in advanced solid tumors, NSCLC, and HNSCC
jRCT2031210386Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ABBV-514 and budigalimab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and Nonhematologic neoplasms (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Maximum observed serum concentration (Cmax) of ABBV-514 and 6 more. Started Jan 2021; status: recruiting.
02
Drugs
ABBV-514budigalimab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210386.